United-Guardian Reports Increased Third Quarter Earnings
United-Guardian reported increased financial results for Q3 and the first nine months of 2024. Nine-month sales grew from $8.28M to $9.71M, with net income rising from $1.84M ($0.40/share) to $2.75M ($0.60/share). Q3 sales remained stable at $3.06M, while net income increased from $627K ($0.14/share) to $865K ($0.19/share). Cosmetic ingredients sales rose 8% in Q3 and 68% in the first nine months. Medical lubricants saw a 2% Q3 decrease but 4% nine-month growth. Pharmaceutical sales declined 6% in Q3 and 11% over nine months due to a Renacidin® supply disruption.
United-Guardian ha riportato un incremento dei risultati finanziari per il terzo trimestre e per i primi nove mesi del 2024. Le vendite nei nove mesi sono aumentate da $8.28M a $9.71M, con un reddito netto che è passato da $1.84M ($0.40/share) a $2.75M ($0.60/share). Le vendite del terzo trimestre sono rimaste stabili a $3.06M, mentre il reddito netto è aumentato da $627K ($0.14/share) a $865K ($0.19/share). Le vendite di ingredienti cosmetici sono aumentate dell'8% nel terzo trimestre e del 68% nei primi nove mesi. I lubrificanti medici hanno registrato un calo del 2% nel terzo trimestre ma una crescita del 4% nei nove mesi. Le vendite farmaceutiche sono diminuite del 6% nel terzo trimestre e dell'11% nei nove mesi a causa di una interruzione nella fornitura di Renacidin®.
United-Guardian reportó resultados financieros en aumento para el tercer trimestre y los primeros nueve meses de 2024. Las ventas en nueve meses crecieron de $8.28M a $9.71M, con un ingreso neto que aumentó de $1.84M ($0.40/share) a $2.75M ($0.60/share). Las ventas del tercer trimestre se mantuvieron estables en $3.06M, mientras que el ingreso neto aumentó de $627K ($0.14/share) a $865K ($0.19/share). Las ventas de ingredientes cosméticos crecieron un 8% en el tercer trimestre y un 68% en los primeros nueve meses. Los lubricantes médicos experimentaron una disminución del 2% en el tercer trimestre pero un crecimiento del 4% en los nueve meses. Las ventas farmacéuticas disminuyeron un 6% en el tercer trimestre y un 11% en los nueve meses debido a una interrupción en el suministro de Renacidin®.
United-Guardian는 2024년 3분기 및 첫 9개월 동안 재무 실적이 증가했다고 보고했습니다. 9개월 매출은 $8.28M에서 $9.71M로 증가했으며, 순이익은 $1.84M ($0.40/share)에서 $2.75M ($0.60/share)로 상승했습니다. 3분기 매출은 $3.06M로 안정세를 유지했으며, 순이익은 $627K ($0.14/share)에서 $865K ($0.19/share)로 증가했습니다. 화장품 성분 매출은 3분기 동안 8%, 첫 9개월 동안 68% 증가했습니다. 의료 윤활제는 3분기 동안 2% 감소했지만 9개월 동안 4% 성장했습니다. 제약 매출은 3분기 동안 6% 감소하고 9개월 동안 11% 감소했으며, 이는 Renacidin® 공급 중단에 기인합니다.
United-Guardian a rapporté une augmentation des résultats financiers pour le troisième trimestre et les neuf premiers mois de 2024. Les ventes sur neuf mois ont augmenté de $8.28M à $9.71M, avec un revenu net passant de $1.84M ($0.40/share) à $2.75M ($0.60/share). Les ventes du troisième trimestre sont restées stables à $3.06M, tandis que le revenu net a augmenté de $627K ($0.14/share) à $865K ($0.19/share). Les ventes d'ingrédients cosmétiques ont augmenté de 8% au troisième trimestre et de 68% au cours des neuf premiers mois. Les lubrifiants médicaux ont vu une baisse de 2% au troisième trimestre mais une croissance de 4% sur neuf mois. Les ventes pharmaceutiques ont diminué de 6% au troisième trimestre et de 11% sur neuf mois en raison d'une interruption de l'approvisionnement en Renacidin®.
United-Guardian berichtete von gestiegenen Finanzergebnissen für das dritte Quartal und die ersten neun Monate 2024. Die Verkäufe in den neun Monaten stiegen von $8.28M auf $9.71M, während das Nettoeinkommen von $1.84M ($0.40/share) auf $2.75M ($0.60/share) anstieg. Die Verkäufe im dritten Quartal blieben stabil bei $3.06M, während das Nettoeinkommen von $627K ($0.14/share) auf $865K ($0.19/share) anstieg. Die Verkäufe von kosmetischen Inhaltsstoffen stiegen im dritten Quartal um 8% und in den ersten neun Monaten um 68%. Medizinische Schmierstoffe verzeichneten einen Rückgang von 2% im dritten Quartal, wuchsen aber um 4% in den neun Monaten. Die pharmazeutischen Verkäufe fielen im dritten Quartal um 6% und in den neun Monaten um 11% aufgrund einer Unterbrechung der Versorgung mit Renacidin®.
- Nine-month revenue increased 17.2% to $9.71M
- Net income grew 49% to $2.75M for nine months
- EPS increased 50% to $0.60 for nine months
- Cosmetic ingredients sales surged 68% in first nine months
- Q3 net income improved 38% to $865K
- Pharmaceutical sales declined 11% over nine months
- Medical lubricants decreased 2% in Q3
- Ongoing supply disruption issues with Renacidin product
Insights
The Q3 2024 results show significant improvement in United-Guardian's financial performance. Net income jumped by
The cosmetic ingredients segment's
HAUPPAUGE, N.Y., Nov. 08, 2024 (GLOBE NEWSWIRE) -- United-Guardian, Inc. (NASDAQ:UG) announced today the financial results for the third quarter and the first nine months of 2024. Sales for the nine-month period ended September 30th increased from
Donna Vigilante, President of United-Guardian, stated, “We are pleased to announce that sales and earnings increased in the third quarter and for the first nine months of 2024 compared with the same periods in 2023. We continue to have strong sales of our cosmetic ingredients, which increased by
United-Guardian is a manufacturer of cosmetic ingredients, pharmaceuticals, medical lubricants, and sexual wellness ingredients.
Contact: Donna Vigilante
(631) 273-0900
dvigilante@u-g.com
NOTE: This press release contains both historical and "forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements about the company’s expectations or beliefs concerning future events, such as financial performance, business prospects, and similar matters, are being made in reliance upon the “safe harbor” provisions of that Act. Such statements are subject to a variety of factors that could cause our actual results or performance to differ materially from the anticipated results or performance expressed or implied by such forward-looking statements. For further information about the risks and uncertainties that may affect the company’s business please refer to the company's reports and filings with the Securities and Exchange Commission.
| Financial Results for the Three and Nine Months Ended September 30, 2024 and 2023 STATEMENTS OF INCOME (unaudited) | ||||||||||||
| THREE MONTHS ENDED SEPTEMBER 30, | NINE MONTHS ENDED SEPTEMBER 30, | |||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||
| Net sales | $ | 3,060,113 | $ | 3,057,518 | $ | 9,705,262 | $ | 8,278,141 | ||||
| Costs and expenses: | ||||||||||||
| Cost of sales | 1,408,866 | 1,749,041 | 4,526,446 | 4,272,043 | ||||||||
| Operating expenses | 591,047 | 488,464 | 1,762,689 | 1,580,503 | ||||||||
| Research and development expense | 111,072 | 98,141 | 325,714 | 353,829 | ||||||||
| Total costs and expenses | 2,110,985 | 2,335,646 | 6,614,849 | 6,206,375 | ||||||||
| Income from operations | 949,128 | 721,872 | 3,090,413 | 2,071,766 | ||||||||
| Other Income (expense): | ||||||||||||
| Investment income | 99,934 | 79,682 | 298,014 | 182,264 | ||||||||
| Net gain (loss) on marketable securities | 47,223 | (14,357 | ) | 79,218 | 65,823 | |||||||
| Total other income | 147,157 | 65,325 | 377,232 | 248,087 | ||||||||
| Income before provision for income taxes | 1,096,285 | 787,197 | 3,467,645 | 2,319,853 | ||||||||
| Provision for income taxes | 230,801 | 160,441 | 720,494 | 475,922 | ||||||||
| Net income | $ | 865,484 | $ | 626,756 | $ | 2,747,151 | $ | 1,843,931 | ||||
| Earnings per common share (Basic and Diluted) | $ | 0.19 | $ | 0.14 | $ | 0.60 | $ | 0.40 | ||||
| Weighted average shares – basic and diluted | 4,594,319 | 4,594,319 | 4,594,319 | 4,594,319 | ||||||||
FAQ
What was United-Guardian's (UG) revenue for Q3 2024?
How much did United-Guardian's (UG) EPS increase in Q3 2024?
What was the growth rate of United-Guardian's (UG) cosmetic ingredients sales in 2024?
Why did United-Guardian's (UG) pharmaceutical sales decline in 2024?
